Proteome-scale docking: Myth and reality

Drug Discovery Today: Technologies

Volumn 10, Issue 3, 2013, Pages

  Rognan, Didier ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLOZAPINE; ENTACAPONE; HEAT SHOCK PROTEIN 70; ISONIAZID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NELFINAVIR; NILITONIB; OLANZAPINE; PROTEIN KINASE C INHIBITOR; SULFAMETHOXAZOLE; SULFONAMIDE; TOLCAPONE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ARTHRITIS; BINDING FREE ENERGY; CALCULATION; CHEMICAL INTERACTION; CHRONIC MYELOID LEUKEMIA; COMPUTER MODEL; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENERGY; HUMAN; LIGAND BINDING; MACROMOLECULE; MOLECULAR DOCKING; MOLECULAR WEIGHT; PEPTIDE LIBRARY; REVIEW; SCORING SYSTEM; STRUCTURAL PROTEOMICS; STRUCTURE ANALYSIS; TOXIC EPIDERMAL NECROLYSIS;

HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEINS; PROTEOME;

EID: 84879237604     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2013.01.003     Document Type: Review

References (43)

1. R. Nair Structural genomics is the largest contributor of novel structural leverage J. Struct. Funct. Genomics 10 2009 181 191
2. Y. Wang PubChem's bioassay database Nucleic Acids Res. 40 2012 D400 D412
3. H.M. Berman The Protein Data Bank Nucleic Acids Res. 28 2000 235 242
4. J. Meslamani sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins Bioinformatics 27 2011 1324 1326
5. L. Xie, and P.E. Bourne Structure-based systems biology for analyzing off-target binding Curr. Opin. Struct. Biol. 21 2011 189 199
6. A. Gaulton ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40 2011 D1100 D1107
7. D. Rognan Chemogenomic approaches to rational drug design Br. J. Pharmacol. 152 2007 38 52
8. R. Morphy Selectively nonselective kinase inhibition: striking the right balance J. Med. Chem. 53 2010 1413 1437
9. Y.Y. Li, and S.J. Jones Drug repositioning for personalized medicine Genome Med. 4 2012 27
10. D. Rognan Structure-based approaches to target fishing and ligand profiling Mol. Inf. 29 2010 176 187
11. M.J. Keiser The chemical basis of pharmacology Biochemistry 49 2010 10267 10276
12. G.J.P. van Westen Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets MedChemComm 2 2011 16 30
13. S.L. McGovern, and B.K. Shoichet Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes J. Med. Chem. 46 2003 2895 2907
14. H. Fan Molecular docking screens using comparative models of proteins J. Chem. Inf. Model. 49 2009 2512 2527
15. S. Perot Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery Drug Discov. Today 15 2010 656 667
16. N. Moitessier Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go Br. J. Pharmacol. 153 Suppl. 1 2008 S7 S26
17. E. Yuriev Challenges and advances in computational docking: 2009 in review J. Mol. Recognit. 24 2011 149 164
18. K.W. Lexa, and H.A. Carlson Protein flexibility in docking and surface mapping Q. Rev. Biophys. 2012 1 43
19. O. Villacanas Explicit treatment of water molecules in protein-ligand docking Curr. Comput. Aided Drug Des. 5 2009 145 154
20. R.D. Smith CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions J. Chem. Inf. Model. 51 2011 2115 2131
21. N. Schneider Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function J. Comput. Aided Mol. Des. 2011
22. F.N. Novikov CSAR scoring challenge reveals the need for new concepts in estimating protein-ligand binding affinity J. Chem. Inf. Model. 51 2011 2090 2096
23. W. Wang The interprotein scoring noises in glide docking scores Proteins 80 2011 169 183
24. L. Hui-fang Evaluation of various inverse docking schemes in multiple targets identification J. Mol. Graph. Model. 29 2010 326 330
25. L. Yang Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome: clozapine-induced agranulocytosis as a case study PLoS Comput. Biol. 7 2011 e1002016
26. G.P. Vigers, and J.P. Rizzi Multiple active site corrections for docking and virtual screening J. Med. Chem. 47 2004 80 89
27. E. Kellenberger Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems J. Chem. Inf. Model. 48 2008 1014 1025
28. Y.Y. Li A computational approach to finding novel targets for existing drugs PLoS Comput. Biol. 7 2011 e1002139
29. M. Brylinski, and J. Skolnick Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening J. Chem. Inf. Model. 50 2010 1839 1854
30. S.L. Kinnings Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis PLoS Comput. Biol. 5 2009 e1000423
31. L. Xie Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir PLoS Comput. Biol. 7 2011 e1002037
32. L. Yang Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome PLoS Comput. Biol. 5 2009 e1000441
33. L. Yang Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome-clozapine-induced agranulocytosis as a case study PLoS Comput. Biol. 7 2011 e1002016
34. L. Yang SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome Nucleic Acids Res. 37 2009 W406 W412
35. H. Luo DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome Nucleic Acids Res. 39 2011 W492 W498
36. Q.T. Do Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin Curr. Drug Discov. Technol. 2 2005 161 167
37. J. Cai Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation Protein Sci. 15 2006 2071 2081
38. P. Muller In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors J. Med. Chem. 49 2006 6768 6778
39. J. Meslamani Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling J. Chem. Inf. Model. 52 2012 943 955
40. P. Bernard Application of drug repositioning strategy to TOFISOPAM Curr. Med. Chem. 15 2008 3196 3203
41. S. Zahler Inverse in silico screening for identification of kinase inhibitor targets Chem. Biol. 14 2007 1207 1214
42. Z. Gao PDTD: a web-accessible protein database for drug target identification BMC Bioinform. 9 2008 104
43. L. Li BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome Nucleic Acids Res. 38 2009 D765 D773